Study of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers

Tianjin Chase Sun Pharmaceutical

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Kukoamine B Mesilate; Drug: placebo multiple doses

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02690961

HR-KB103

ChiCTR-TRC-14005111 (Registry Identifier)

Details and patient eligibility

About

The purpose of this study is to assess safety, tolerance and pharmacokinetics of Multiple-dose Kukoamine B Mesilate in healthy volunteers

Enrollment: 24 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Gender: male or female, each sex ratio does not exceed 2/3;
2. 18-45 years (including upper and lower limit), the general situation is good;
3. Body mass index (BMI) in 19-28 (including upper and lower limit of the range), bodyweight（BW）≥ 50kg (female) and 60kg (male);
4. Nearly half of the year, no child care program and agreed to take effective measures to contraception during the study period, women of childbearing age blood pregnancy test was negative;
5. Subjects to fully understand the purpose, properties, method and reactions may occur of test drug trials.Voluntarily signed the informed consents, and agreed to abide by the requirements of clinical protocols.

Exclusion criteria

1. Primary disease in important organs;
2. Mental or physical disability;
3. Familial hereditary disease;
4. Screening supine blood pressure (after 5 minutes of rest) systolic or diastolic blood pressure greater than 90-140 millimeters of mercury(mmHg), beyond the scope of 50-90 millimeters of mercury(mmHg), Or pulse (HR) beyond 50bpm-100bpm;
5. Abnormal results of any clinically meaningful physical examination, vital signs, ECG or clinical laboratory;
6. History of immunodeficiency diseases, including HIV antibody positive;
7. Detection of antibody positive, hepatitis B surface antigen or antibody to hepatitis C / syphilis positive;
8. Alcohol and drug abusers;
9. Who is addicted to alcohol and tobacco (drinking 14 units of alcohol per week: 1 unit = beer 285 ml, or liquor 25 ml, or wine 1 cup. numbers of daily smoking ≥ 5) and / or not smoking and drinking in the test period;
10. Any discharge period may affect the study drug, or in the past 3 months participated in any drug clinical trials;
11. Before entering the group 4 weeks using any prescription drugs before entering the group, or use of any non prescription drugs within 2 weeks (vitamins, herbal tonics, etc.), or into the group within 2 weeks before taking effect of drug metabolizing enzymes in food, such as grapefruit or grapefruit drink. Can the use of acetaminophen, but must record report in case report form（CRF）;
12. The last 3 months had a history of blood donation or significant blood loss (more than 400ml);
13. There are drugs, the clinical significance of the history of food allergy and atopic allergic diseases (asthma, urticaria, eczema dermatitis) or a known drug to test drugs or similar drug allergy test;
14. Lactating women, pregnant women or unable to take effective contraceptive measures;
15. Researchers believe that participants not suitable to take the test for other factors .

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

24 participants in 6 patient groups

Kukoamine B Mesilate 0.06mg/kg

Experimental group

Description:

Dose Escalation: Kukoamine B Mesilate 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Treatment:

Drug: Kukoamine B Mesilate

Kukoamine B Mesilate 0.12mg/kg

Experimental group

Description:

Dose Escalation: Kukoamine B Mesilate 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Treatment:

Drug: Kukoamine B Mesilate

Kukoamine B Mesilate 0.24mg/kg

Experimental group

Description:

Dose Escalation: Kukoamine B Mesilate 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Treatment:

Drug: Kukoamine B Mesilate

Placebo 0.06mg/kg

Experimental group

Description:

Dose Escalation: placebo 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Treatment:

Drug: placebo multiple doses

Placebo 0.12mg/kg

Experimental group

Description:

Dose Escalation: placebo 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Treatment:

Drug: placebo multiple doses

Placebo 0.24mg/kg

Experimental group

Description:

Dose Escalation: placebo 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Treatment:

Drug: placebo multiple doses